Liu L W, Zhao X Y, Jia J D
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Diseases, Beijing 100050, China.
Zhonghua Gan Zang Bing Za Zhi. 2019 Jun 20;27(6):420-423. doi: 10.3760/cma.j.issn.1007-3418.2019.06.006.
Idiosyncratic (unpredictable) drug-induced liver injury (iDILI) is one of the most challenging liver diseases encountered by hepatologists due to its diverse clinical and pathological manifestations and lack of specific diagnostic markers. An increasing awareness of iDILI diagnosis and carefully excluding liver damage induced by other causes is the key to a proper diagnosis of iDILI. However, delayed diagnosis, inappropriate monitor and care leads to serious clinical consequences, such as acute liver failure or even liver-related death. In addition, there is presently no effective treatment for iDILI. Herein, we presented the main recommendations of the recent EASL published first DILI guidelines into Chinese language to facilitate liver disease authors and health workers to understand the latest research progress of DILI.
特异质性（不可预测的）药物性肝损伤（iDILI）是肝病学家所面临的最具挑战性的肝脏疾病之一，因其临床和病理表现多样且缺乏特异性诊断标志物。提高对iDILI诊断的认识并仔细排除其他原因引起的肝损伤是正确诊断iDILI的关键。然而，诊断延迟、监测和护理不当会导致严重的临床后果，如急性肝衰竭甚至肝相关死亡。此外，目前尚无治疗iDILI的有效方法。在此，我们将欧洲肝脏研究学会（EASL）近期发布的首个药物性肝损伤指南的主要建议翻译成中文，以方便肝病领域的作者和卫生工作者了解药物性肝损伤的最新研究进展。
